Efanesoctocog alfa is under clinical development by Sanofi and currently in the Phase I and Pre-Registration in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Efanesoctocog alfa’s likelihood of approval (LoA) and phase transition for Hemophilia A (Factor VIII Deficiency) took place on 01 Sep 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Efanesoctocog alfa Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Efanesoctocog alfa overview
Efanesoctocog alfa (BIVV-001) (rFVIIIFc-XTEN-vWF fusion molecule) is under development for the treatment of hemophilia A and Von Willebrand's Disease. FVIII is a glycoprotein procofactor. The drug candidate is administered through intravenous route. The drug candidate is a recombinant coagulation factor VIII Fc-Von Willebrand factor-XTEN fusion protein. It is developed based on XTEN technology. BIVV-001 acts by targeting coagulation factor VIII.
Sanofi is a healthcare company, which is engaged in the discovery, development, manufacturing and marketing of a wide range of medicines and vaccines. Its portfolio includes medicines for the treatment of cancer, diabetes, rare diseases, multiple sclerosis and cardiovascular diseases; human vaccines for protection against various bacterial and viral diseases; and other products. The company also offers consumer healthcare products for digestion; allergy; cough, cold, flu and sinus; pain; women’s health; and vitamins, minerals and supplements. Sanofi‘s R&D efforts focus on advancing a combination drugs to increase the effectiveness of treatments and on advancing the formulation of new biologics to produce precision medicines. It has operations in Europe, the Americas, Asia-Pacific, Africa and the Middle East. Sanofi is headquartered in Paris, France.
Quick View Efanesoctocog alfa LOA Data
|Highest Development Stage|